We’re heading into the traditional charitable giving season. You should start your planning early this year to make sure you incorporate tax law changes for 2013, and a few changes from the last 10 years that many people still haven’t absorbed. Here’s a guide to securing 2013 write offs.
Higher income people should keep in mind two key tax code changes. First, the top tax rate was raised. A 39.6% rate now applies to married taxpayers filing jointly with taxable incomes of $450,000 or more and singles earning $400,000 or more.
On the negative side, the Pease limitation (named after a former congressman) on itemized deductions is reinstated. Most itemized deductions on Schedule A are reduced, including charitable contributions, by 3% of the amount by which adjusted gross income exceeds the income threshold. For married taxpayers filing jointly, the threshold is $300,000, and for singles it is $250,000. Itemized deductions can’t be reduced by more than 80% under the provision.
Top 10 Integrated Utility Companies For 2015: Universal Electronics Inc.(UEIC)
Universal Electronics Inc. develops and manufactures pre-programmed wireless remote control products, audio-video accessories, and software products. The company offers infrared and radio frequency remote controls; audio-video accessories; integrated circuits; and software, firmware, and technology solutions, which enable devices, such as televisions, set-top boxes, stereos, automotive audio systems, cell phones, and other consumer electronic devices to wirelessly connect and interact with home networks and interactive services to deliver digital entertainment and information. It is also involved in intellectual property licensing activities. The company sells its products directly, as well as through distributors in Europe, Australia, New Zealand, South Africa, the Middle East, Mexico, Asia, and Latin America under the One For All and Nevo brands. It primarily serves cable and satellite television service providers, original equipment manufacturers, retailers, custom inst allers, software development companies, private label companies, and personal computing companies. Universal Electronics Inc. was founded in 1986 and is headquartered in Cypress, California.
Advisors' Opinion:- [By , Zacks Investment Research]
Universal Electronics (UEIC) makes a broad line of pre-programmed universal remote control products, audio-video accessories, and software that are marketed to enhance home entertainment systems. Its customers include subscription broadcasters (i.e., DirecTV (DTV)), original equipment manufacturers (“OEMs”), international retailers, private labels, and companies in the computing industry. Approximately 63% of its sales came from outside the U.S. in the first quarter of 2014. It has a market cap of $645 million.
Hot Dow Dividend Companies To Buy Right Now: Ur Energy Inc(URG)
Ur-Energy Inc., an exploration stage junior mining company, engages in the identification, acquisition, evaluation, exploration, and development of uranium mineral properties. The company has 13 projects located in Wyoming and Nebraska, the United States; and 3 exploration projects located in the Northwest Territories and Nunavut, Canada. Its landholdings cover approximately 90,000 acres in the United States and approximately 140,000 acres in Canada. The company was founded in 2004 and is headquartered in Littleton, Colorado.
Advisors' Opinion:- [By John Udovich]
Small cap nuclear fuel stock USEC Inc (NYSE: USU) is up some 300% this week���meaning its worth taking a closer look at the company along with the performance potential uranium or nuclear stock peers Uranium Resources, Inc (NASDAQ: URRE), Denison Mines Corp (NYSEMKT: DNN), Ur-Energy Inc (NYSEMKT: URG) and Uranerz Energy Corp (NYSEMKT: URZ).
Hot Dow Dividend Companies To Buy Right Now: Codexis Inc.(CDXS)
Codexis, Inc. engages in the production of custom industrial enzymes for use in the manufacture of biofuels, chemicals, and pharmaceutical ingredients. The company offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. It also provides enzyme screening services, enzyme optimization services, and enzymes, as well as supplies intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, the company develops CodeXyme cellulase enzymes to convert cellulosic biomass, a non-food plant material into affordable sugars, which can then be converted into renewable fuels and chemicals; and CodeXol detergent alcohols that are used to manufacture surfactants, which are used as cleaning ingredients in consumer products, such as shampoos, liquid soaps, and laundry detergents. It intends to market CodeXyme cellulase enzymes to chemicals manufacturers; and CodeXol detergent alcohols as a drop-in substitute for the detergent alcohols market. The company has strategic collaborations with Royal Dutch Shell plc and Iogen Energy Corporation for the production of cellulosic ethanol from wheat straw and corn stover feedstocks. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Advisors' Opinion:- [By Maxx Chatsko]
There have been two pops of at least 20% for industrial biotech in the last week -- both on the heels of expected news, nonetheless. Last week Codexis (NASDAQ: CDXS ) announced that it successfully completed a demonstration facility in Italy for its CodeXol detergent alcohols with partner Chemtex. It is a step in the right direction, but more sustainable share movements will come with courting commercial partners. The two still have plenty of work to collect production metric data and move into commercial scale with a bigger partner.
- [By Laura Brodbeck]
Tuesday
Earnings Expected: The Bon-Ton Stores, Inc (NASDAQ: BONT), American Eagle Outfitters, Inc (NYSE: AEO), Codexis, Inc. (NASDAQ: CDXS), Verifone Systems, Inc. (NYSE: PAY), Caesars Entertainment Corporation (NASDAQ: CZR) Economic Releases Expected: Indian trade balance, German trade balance, British industrial production, British manufacturing productionWednesday
- [By Maxx Chatsko]
Synthetic biology company and industrial bio-enzyme manufacturer�Codexis (NASDAQ: CDXS ) announced its first-quarter earnings after the market closed Tuesday. The industrial enzyme firm is still attempting to get back on its feet after Shell (NYSE: RDS-A ) ended a major collaboration in the second half of 2012. The partnership provided more than $350 million to Codexis over several years, so it is easy to see how the developmental-stage company has foundered since. Despite continued losses, it appears that Codexis is slowly climbing back to a bright future. Here is what investors need to know about the latest developments.
Hot Dow Dividend Companies To Buy Right Now: China Telecom Corp Ltd (CHA)
China Telecom Corporation Limited, together with its subsidiaries, provides wireline and mobile telecommunications services in the People's Republic of China. The company?s services include wireline voice, mobile voice, Internet, managed data and leased line, value-added services, integrated information application services, and other related services, as well as prepaid calling cards. Its wireline voice services include local wireline services, domestic long distance wireline services, and international long distance wireline services. The company's mobile voice services comprise local calls, domestic long distance calls, international long distance calls, intra-provincial roaming, inter-provincial roaming, and international roaming. Its Internet access services consist of wireline Internet access services, including dial-up and broadband services, and wireless Internet access services. The company's integrated information application services include Best Tone services, which provide customers with phone number storage, enquiry, and call transfer services; and information technology-based integrated solutions, such as system integration, outsourcing, special advisory, information application, knowledge services, and software development. Its managed data and leased line services consist of services relating to optic fiber and circuits, such as optic fiber and circuit leasing, virtual private network, and bandwidth leasing. The company also offers other services, such as sales, rental, repairs, and maintenance of equipment; and provides consulting services, and e-commerce and booking services, as well as in the sale of telecommunications terminals. It serves government, enterprise, and residential customers. The company was founded in 2002 and is based in Beijing, the People's Republic of China. China Telecom Corporation Limited is a subsidiary of China Telecommunications Corporation.
Advisors' Opinion:- [By Doug Young]
I've been writing about the VNO development for awhile now, as it's really quite exciting with the potential to instantly triple the number of telecoms service providers in the market from the current three to a new field of 8-9 operators. Equally important, most of those new operators, which would lease network capacity from the existing three telcos, are private sector firms. That means they should be much more nimble and innovative than the current monopoly of three big state-run companies, China Mobile, China Unicom (CHU) and China Telecom (CHA).
- [By Dividend]
China Telecom (CHA) has a market capitalization of $42.51 billion. The company employs 305,676 people, generates revenue of $46.253 billion and has a net income of $2.457 billion. China Telecom�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $12.171 billion. The EBITDA margin is 26.32 percent (the operating margin is 7.48 percent and the net profit margin 5.31 percent).
- [By Jim Woods]
China Telecom (CHA) has seen its shares fall more than 16% over the past year, with much of that coming in 2014. China Unicom (CHU) stock has slumped 9% in the past 52 weeks, thanks to a 12% decline year-to-date.
Hot Dow Dividend Companies To Buy Right Now: Cato Corp (CATO)
The Cato Corporation (Cato) is a women�� fashion specialty retailer. As of January 28, 2012, the Company operated 1,288 fashion specialty stores in 31 states, principally in the southeastern United States, under the names Cato, Cato Fashions, Cato Plus, It�� Fashion, It�� Fashion Metro and Versona Accessories. It operates in two segments: stores and Credit. The Company�� stores offer a assortment of on-trend apparel and accessory items in primarily junior/missy, plus sizes, girls sizes 7 to 16, men�� and kids sizes newborn to seven. Its merchandise lines include dressy, career, and casual sportswear, dresses, coats, shoes, lingerie, costume jewelry, handbags, men�� wear and lines for kids and newborns. Its merchandise is sold under its private label and is produced by various vendors in accordance with the Company�� specifications.
The Company offers its own credit card and a layaway plan to make the purchase of its merchandise convenient for its customers. The Company�� stores are located in the southeastern United States in a variety of markets ranging from small towns to metropolitan areas with trade area populations of 20,000 or more. Stores average approximately 4,500 square feet in size. The Company offers its own credit card, which accounted for 4.8% of retail sales during the fiscal year ended January 28, 2012 (fiscal 2012).
Advisors' Opinion:- [By Rich Duprey]
Clothing retailer�Cato� (NYSE: CATO ) �announced yesterday�its second-quarter dividend of $0.05 per share, the same rate it paid last quarter after paying a special dividend of $1.00 per share in December.
- [By Jake L'Ecuyer]
The Cato (NYSE: CATO) was down, falling 6.35 percent to $28.19 on Q4 results. Cato reported its Q4 earnings of $0.13 per share, versus analysts' estimates of $0.13 per share. Cato Corporation expects FY14 earnings of $1.47 to $1.66 per share, versus estimates of $1.86 per share.
- [By Reuters]
Joshua Lott/Getty Images NEW YORK -- Several major U.S. retailers posted disappointing sales for November after cautious shoppers pinched their pennies at the start of a shorter holiday season. Some of the companies that reported sales gains ramped up bargains to bring in shoppers who appeared hesitant to splurge. Costco Wholesale (COST) said Thursday that sales at stores open at least a year rose 2 percent, below the 3.3 percent increase analysts were looking for, according to Thomson Reuters. The warehouse club chain said consumer electronics sales fell. Same-store sales at L Brands (LTD), owner of the Victoria's Secret lingerie chain, also came in below expectations. Its drop of 5.5 percent was far deeper than the 1.1 percent decline analysts were projecting. Wall Street analysts are expecting 11 top retailers to report a 2.7 percent increase in same-store sales for November, according to Thomson Reuters. Excluding drugstore operators, which get two-thirds of revenue from prescriptions, that gain is estimated at 2.3 percent. Gap (GPS) will report its November sales after U.S. markets close. Retailers have been contending with low consumer confidence and the need to prod shoppers with bargains this holiday season, which has six fewer days because of a late Thanksgiving. The National Retail Federation on Sunday said U.S. shoppers had spent 2.9 percent less this year over the Thanksgiving weekend, the kickoff to the holiday season. The Conference Board, an industry group, said last week that U.S. consumer confidence fell in November after a sharp drop in October as Americans worried about their future jobs and earnings prospects. Earlier this week, J.C. Penney (JCP) reported a 10.1 percent comparable sales increase, partially reversing a disastrous decline in 2012, but the department store chain had to resort to aggressive bargains. The "environment will remain as competitive" through the holiday season, Chief Executive Officer Myron Ullman said. I
- [By Jake L'Ecuyer]
The Cato (NYSE: CATO) was down, falling 11.89 percent to $26.52 on Q4 results. Cato reported its Q4 earnings of $0.13 per share, versus analysts' estimates of $0.13 per share. Cato Corporation expects FY14 earnings of $1.47 to $1.66 per share, versus estimates of $1.86 per share.
Hot Dow Dividend Companies To Buy Right Now: Titan Pharmaceuticals Inc (TTNP.OB)
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine
Probuphine is the first product to utilize the Company�� ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine
Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
Advisors' Opinion:- [By C.R. Jackson]
Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.
Hot Dow Dividend Companies To Buy Right Now: Gastar Exploration Ltd (GST)
Gastar Exploration Ltd (Gastar) is an independent energy company engaged in the exploration, development and production of natural gas and oil in the United States. The Company�� principal business activities include the identification, acquisition, and subsequent exploration and development of natural gas and oil properties with an emphasis on unconventional reserves, such as shale resource plays. As of December 31, 2011, it is pursuing the development of liquids-rich natural gas in the Marcellus Shale in the Appalachia area of West Virginia and, to a lesser extent, central and southwestern Pennsylvania. The Company also holds prospective acreage in the deep Bossier play in the Hilltop area of East Texas and conduct limited coal bed methane (CBM) development activities within the Powder River Basin of Wyoming and Montana. The Company is a holding company. Advisors' Opinion:- [By Heather Ingrassia]
Gastar Agreement: On April 1st it was announced that Gastar Exploration, Ltd. (GST) had entered into a definitive agreement to acquire proven reserves and undeveloped leasehold interests in Kingfisher and Canadian counties of Oklahoma from Chesapeake Energy Corporation, repurchase Chesapeake's common shares of the Company and settle all litigation for $1 million. Although smaller in scope than most of Chesapeake's previous asset-shedding transactions, the agreement with Gastar accomplishes two things. First, is the fact the settlement resolves the legal wrangling both companies were engaged in and as a result Chesapeake walks away with $85 million of the potential $130 million they were suing for. Second, is the fact Chesapeake wipes it hands of acreage, that although producing, may not be producing as much as Chesapeake had once hoped, and therefore was worth much more to Gastar in the long run.
- [By David Smith]
Earlier, the company had pocketed $75.2 million by selling to Gastar Exploration (NYSEMKT: GST ) leasehold acreage in Oklahoma's Kingfisher and Canadian counties. It'll obviously require a passel of sales of that magnitude to shore up an overweight balance sheet.
No comments:
Post a Comment